ANTI-FAS ON NONHEMATOPOIETIC TUMORS - LEVELS OF FAS/APO-1 AND BCL-2 ARE NOT PREDICTIVE OF BIOLOGICAL RESPONSIVENESS

被引:0
|
作者
OWENSCHAUB, LB
RADINSKY, R
KRUZEL, E
BERRY, K
YONEHARA, S
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030
[2] JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA 236,JAPAN
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fas/APO-1 is a cell surface protein known to trigger apoptosis in a variety of cell types upon specific antibody binding. Although extensively studied on normal and malignant hematopoietic cells, little is known about Fas/APO-1 on nonhematopoietic cells. In the study presented here, we have examined Fas/APO-1 expression and function on 11 human tumors of nonhematopoietic origin. By dow cytometric analysis, Fas/APO-1 was expressed on 10 of the 11 tumors at levels comparable to those previously reported for lymphoid cells sensitive to the cytolytic effects of anti-Fas. Despite abundant cell surface expression, only 4 of the 10 Fas-positive tumors were sensitive to the cell-killing effects of anti-Fas. Moreover, anti-Fas enhanced the growth of 2 of 10 Fas-positive tumors. Additional studies using cycloheximide demonstrated that de novo protein synthesis was required for anti-Fas-triggered growth stimulation and, at least in one case, was responsible for the resistance to antibody-induced apoptosis. The biological effects initiated by anti-Fas engagement, however were not correlated with endogenous bcl-2 expression. This report documents that: (a) Fas/APO-1 is widely expressed on cultured nonhematopoietic tumors; (b) the inherent susceptibility to anti-Fas-induced apoptosis is not correlated with expression of the Fas/APO-1 protein; (c) Fas/APO-1 engagement can result in growth enhancement; and (d) protective/growth-promoting proteins other than bcl-2 may contribute to the diverse spectrum of biological effects induced by anti-Fas engagement of the Fas/APO-1 protein.
引用
收藏
页码:1580 / 1586
页数:7
相关论文
共 50 条
  • [41] Specificity of anti-human CD95 (APO-1/Fas) antibodies
    Schmitz, I
    Krueger, A
    Baumann, S
    Kirchhoff, S
    Krammer, PH
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 297 (03) : 459 - 462
  • [42] Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease
    Goel, N
    Ulrich, DT
    StClair, EW
    Fleming, JA
    Lynch, DH
    Seldin, MF
    ARTHRITIS AND RHEUMATISM, 1995, 38 (12): : 1738 - 1743
  • [43] Sensitivity of S49.1 cells to anti-CD95 (Fas/Apo-1)-induced apoptosis: effects of CD95, bcl-2 or bcl-x transduction
    Broome, HE
    Dargan, CM
    Brunner, T
    Green, DR
    CELL DEATH AND DIFFERENTIATION, 1998, 5 (03): : 200 - 205
  • [44] Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis
    Jakobson, E
    Jönsson, G
    Björck, P
    Paulie, S
    INTERNATIONAL JOURNAL OF CANCER, 1998, 77 (06) : 849 - 853
  • [45] Bcl-2 gene transfer protects human hepatoma cells from apoptotic change induced by anti-Fas antibody
    Takahashi, M
    Saito, H
    Ebinuma, H
    Ohishi, T
    Kaneko, F
    Okuyama, T
    Ishii, H
    GASTROENTEROLOGY, 1997, 112 (04) : A1394 - A1394
  • [46] Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T Lymphocytes by the protooncogene bcl-2
    Schroter, M
    Lowin, B
    Borner, C
    Tschopp, J
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (12) : 3509 - 3513
  • [47] 凋亡相关基因产物Fas/APO-1和Bcl-2蛋白在肺癌组织中的表达及意义
    易云峰
    甘旭坤
    林村河
    胡新杰
    肺癌杂志, 1999, (01) : 3 - 5
  • [48] 凋亡相关基因产物Fas/APO-1和bcl-2蛋白在肾癌组织中的表达及意义
    李宏军
    俞莉章
    杨宝龙
    孔祥田
    宓培
    郭应禄
    中华外科杂志, 1998, (07) : 25 - 27
  • [49] Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors
    Tateyama, H
    Eimoto, T
    Tada, T
    Inagaki, H
    Hattori, H
    Takino, H
    MODERN PATHOLOGY, 1997, 10 (10) : 983 - 991
  • [50] Sensitivity of S49.1 cells to anti-CD95 (Fas/APO-1)-induced apoptosis; Effects of CD95, Bcl-2, or Bcl-x transduction.
    Broome, HE
    Dargan, CM
    Brunner, T
    Green, DR
    BLOOD, 1997, 90 (10) : 3470 - 3470